NSAID use associated with future stroke in healthy population
Brain/Kidney/Peripheral
NSAID use associated with future stroke in healthy population
1 COMMENT - Sep 8, 2010 10:00 EDT
The results are in line with the increased risk of MI seen with NSAIDs and strengthen the need for more careful regulation of these drugs, the study author says.
Featured news
Arrhythmia/EP
First Europe-specific guidance on AF
1 COMMENT - Sep 7, 2010 17:15 EDT
The European Society of Cardiology announced new clinical guidelines for atrial fibrillation at its congress in Stockholm last week, the first time such recommendations have been prepared by European societies acting alone. Highlights include guidance on the use of dronedarone, better risk profiling for stroke in anticipation of new oral anticoagulants, the formal acceptance of ablation as a treatment option, and the recognition that lenient rate control is a satisfactory alternative to strict control.
SHIFT: Adding HR-slowing agent ivabradine to HF meds cuts mortality, hospitalization
Heart failure
SHIFT: Adding HR-slowing agent ivabradine to HF meds cuts mortality, hospitalization
19 COMMENTS - Aug 29, 2010 05:00 EDT
UPDATED WITH COMMENTARY // The trial suggests that heart-rate reduction could become a clinically important goal and in fact a treatment target on its own in patients with chronic heart failure. Questions are raised, however, about how the patients who received ivabradine would have fared if more of them had been optimally treated with beta blockers.
View all »
Editorial series
A series of discussions among editorial leaders, developed by theheart.org

AVERROES, SHIFT, and the Alpha Omega Trial: The Stockholm Survey from ESC 2010
The Cardiology Show
AVERROES, SHIFT, and the Alpha Omega Trial: The Stockholm Survey from ESC 2010
Sep 1, 2010 11:25 EDT
Dr Valentin Fuster sits down with Drs Keith Fox, Kornelia Kotseva, Cecilia Linde, Franz Messerli, Harvey White, and Clyde Yancy to talk about the key trials presented at the ESC 2010 Congress.
ESC 2010 research highlights: A slideshow presentation
Editorial series
ESC 2010 research highlights: A slideshow presentation
Sep 7, 2010 15:30 EDT
For a definitive overview of top clinical trials at ESC 2010 Congress, read our slideshow with the latest findings from AVERROES, SHIFT, ALPHA OMEGA, EINSTEIN DVT, FUTURA OASIS-8, LESSON 1, PLATO genetic substudies, CURE/ACTIVE A, INNOVATE PCI, ATOLL, COPPS, RESPONSE, and STAR-heart.
73-year-old male with respiratory failure
Editorial series
73-year-old male with respiratory failure
Aug 5, 2010 16:30 EDT
Review the echocardiograms and decide what is the most likely diagnosis.
Life and times of leading cardiologists with Rob Califf. Guest: Ralph Brindis
Editorial series
Life and times of leading cardiologists with Rob Califf. Guest: Ralph Brindis
Aug 4, 2010 09:30 EDT
From "exit 9" to ACC presidency, with stops along the way at prep school, MIT, Emory, UCLA, UCSF, and Kaiser Permanente, learn what makes Dr Ralph Brindis tick.
News
STS registry data on bypass surgery published for consumers
Sep 8, 2010 17:30 EDT
Risk-adjusted coronary bypass surgery outcomes data from one-fifth of US heart-surgery programs is now available to the public.
Acute Coronary Syndromes
Evidence of stress in hair predicts AMI
Sep 8, 2010 16:00 EDT
Canadian researchers find that chronic stress that leads to MI is signaled by high cortisol concentrations in the patient's hair.
Lipid/Metabolic
UK experts advised rosiglitazone withdrawal in July
Sep 8, 2010 15:30 EDT
It has emerged this week that UK experts recommended the withdrawal of the diabetes drug rosiglitazone from the British market in July, although this recommendation was not made public at the time. However, because the drug was approved centrally by the European Medicines Agency, only it can revoke the license, says the UK regulatory body; the EMA is discussing rosiglitazone today, although no final decision is expected on the product until the end of this month.
Clinical cardiology
FDA does U-turn on midodrine; will keep it available
3 COMMENTS - Sep 7, 2010 13:30 EDT
The US FDA has done a U-turn on its decision two weeks ago to withdraw midodrine, a drug for orthostatic hypotension. The agency told heartwire it will allow patients continued access to the drug while it tries to resolve the issue of concern: postmarketing studies with the product.
Heart failure
CRT durability showcased in CARE-HF long-term analysis
Sep 3, 2010 14:30 EDT
One of the questions it sheds light on: if CRT is delayed in patients who qualify for it, will later device implantation recapture the lost early survival gains CRT would likely have provided?
Acute Coronary Syndromes
Nurse program provides good RESPONSE for ACS secondary prevention
2 COMMENTS - Sep 3, 2010 13:15 EDT
Reasonably good results were obtained using nurses to counsel patients on secondary prevention after ACS, with a 17% relative reduction in calculated 10-year mortality over and above that achieved with usual care in the RESPONSE study. Although more work needs to be done to better refine such programs, they are feasible and can be easily implemented worldwide, said the researcher and other commentators.
Medscape Medical News
Intensive blood-pressure control does not slow kidney disease in black patients
Sep 3, 2010 10:00 EDT
With the exception of patients with a protein/creatinine ratio of more than 0.22, blood-pressure control does not appear to slow progression of kidney disease in black patients.
Medscape Medical News
SCOUT: Sibutramine linked to increased risk of nonfatal vascular events in subjects with preexisting cardiovascular conditions
Sep 3, 2010 09:00 EDT
Subjects with preexisting CVD given long-term sibutramine treatment had an increased risk of nonfatal MI and nonfatal stroke but not of CV or all-cause death.
MediaPulse
Another Maryland cardiologist in hot water over unnecessary procedures
3 COMMENTS - Sep 2, 2010 10:30 EDT
Another cardiologist in Maryland has been accused of performing unwarranted procedures on multiple patients over a number of years. Dr John R McClean faces criminal charges and a possible 40 years in prison if convicted on all counts.
Interventional/Surgery
CURRENT-OASIS 7 published: Double-dose clopidogrel in PCI debated
3 COMMENTS - Sep 1, 2010 17:00 EDT
Although there was no benefit of doubling the clopidogrel dose in the overall ACS population studied, benefits were suggested in the PCI subgroup. But are these robust enough?
Most popular
  1. Another Maryland cardiologist in hot water over unnecessary procedures
  2. First Europe-specific guidance on AF
  3. FDA does U-turn on midodrine; will keep it available
  4. CURRENT-OASIS 7 published: Double-dose clopidogrel in PCI debated
  5. The "MacStatin": Fast food with some ketchup, salt, and a statin to go
  6. SHIFT: Adding HR-slowing agent ivabradine to HF meds cuts mortality, hospitalization
  7. Adoption of Guideline-Recommended Care in Heart Failure: Two-Year Results From IMPROVE HF
  8. ESC guidelines give top recommendation to CRT for mild heart failure
  9. Calcium supplements boost heart-attack risk: Meta-analysis
  10. AVERROES: Apixaban yields significant reductions in stroke, no increased bleeding
View all news »
  1. SHIFT: Adding HR-slowing agent ivabradine to HF meds cuts mortality, hospitalization
  2. Exercise can treat cardiovascular disease as well as prevent it
  3. The cause of the ST-segment elevation
  4. Alpha Omega Trial: n-3 fatty acids fail to reduce cardiovascular events in post-MI patients
  5. ESC guidelines give top recommendation to CRT for mild heart failure
  6. Pill pickle: Hypotension drug quandary spotlights tough FDA's dilemma
  7. Who's the boss? White House recommends physicians join hospitals, large groups
  8. Another Maryland cardiologist in hot water over unnecessary procedures
  9. FDA does U-turn on midodrine; will keep it available
  10. CURRENT-OASIS 7 published: Double-dose clopidogrel in PCI debated
View all discussions »
Membership is free!

The Heart of a Woman
The Heart of a Woman Programs to aid healthcare professionals in diagnosing, screening, and managing women who have or are at risk for CVD and stroke.

View all programs »
Press center
Latest cardiology-related press releases and communications from industry
Also on theheart.org
ESC 2010 research highlights: A slideshow presentation
Editorial series
ESC 2010 research highlights: A slideshow presentation
Sep 7, 2010 15:30 EDT
For a definitive overview of top clinical trials at ESC 2010 Congress, read our slideshow with the latest findings from AVERROES, SHIFT, ALPHA OMEGA, EINSTEIN DVT, FUTURA OASIS-8, LESSON 1, PLATO genetic substudies, CURE/ACTIVE A, INNOVATE PCI, ATOLL, COPPS, RESPONSE, and STAR-heart.
Arguments continue over the metabolic syndrome
Features
Arguments continue over the metabolic syndrome
17 COMMENTS - Jul 27, 2010 14:15 EDT
The metabolic syndrome has been the subject of controversy for many years: to this day, agreement cannot be reached between the diabetes and cardiology communities about the validity of naming and treating this clustering of certain risk factors as a separate condition.
What Happened at ACC 2010? A McMaster University Perspective
Educational Partnerships
What Happened at ACC 2010? A McMaster University Perspective
Mar 24, 2010 10:22 EDT
Join Drs. Mehta, Eikelboom, Gupta, and Weitz from McMaster University as they discuss the latest data to come out of the 2010 sessions of the American College of Cardiology in Atlanta, Georgia.